Table 4 |
||||
|
New chemical entities (NCEs) approved between 1975 and 1999 by drug class and relative to disease burden and drug sales [9] |
||||
|
Therapeutic areas |
Approved NCEs 1975–1999 |
Proportion of worldwide sales Year 1999 |
NCEs by DALY |
Drug sales (millions of US$) by DALY |
|
|
||||
|
Central nervous system |
211 (15·1%) |
15·1% |
1·32 |
193 |
|
Cardiovascular |
179 (12·8%) |
19·8% |
1·25 |
283 |
|
Cytostatics (neoplasms) |
111 (8·0%) |
3·7% |
1·31 |
90 |
|
Respiratory (non-infectious) |
89 (6·4%) |
9·3% |
1·44 |
307 |
|
Anti-infectives and antiparasitics |
224 (16·1%) |
10·3% |
0·55 |
52 |
|
HIV/AIDS |
26 (1·9%) |
1·5% |
0·37 |
44 |
|
Tuberculosis |
3 (0·2%) |
0·2% |
0·11 |
11 |
|
Tropical diseases (Total) |
13 (0·9%) |
0·2% |
0·10 |
3 |
|
Malaria |
4 (0·3%) |
0·1% |
0·10 |
5 |
|
Other therapeutic categories |
579 (41·6%) |
41·9% |
1·10 |
163 |
|
|
||||
|
Total |
1393 (100%) |
100% |
1·01 |
148 |
|
|
||||
|
Boutayeb International Journal for Equity in Health 2007 6:20 doi:10.1186/1475-9276-6-20 |
||||
